HBM Healthcare Expands Investment in ADARx Pharmaceuticals

HBM Healthcare Investments AG has increased its investment in ADARx Pharmaceuticals following ADARx's successful initial public offering (IPO) on the Nasdaq Global Select Market. The IPO, completed on 25 September 2026, priced at USD 17.00 per share, involved the issuance of 26.25 million new shares, raising approximately USD 446.25 million in gross proceeds.

Initially, HBM invested USD 4 million in ADARx during a Series C financing round in August 2023. The firm has now added USD 15.3 million through the IPO, bringing its total investment to USD 19.3 million and securing a 1.2 percent stake in ADARx. This stake is valued at USD 25.4 million based on the closing price on the first trading day.

ADARx Pharmaceuticals focuses on developing siRNA therapeutics for treating a range of diseases. Its leading candidate, onvuzosiran, is in Phase 3 for hereditary angioedema, with further programs targeting complement-mediated diseases and thrombosis-related disorders.